Sierra Oncology, Inc. (SRRA) Financial Statements (2024 and earlier)

Company Profile

Business Address 1820 GATEWAY DRIVE
SAN MATEO, CA 94404
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 104,749104,055147,528106,046100,348109,007
Cash and cash equivalents 104,749104,055147,528106,046100,348109,007
Receivables 14731119791410370
Prepaid expense 1,029991918555478511
Other current assets 642792401475247247
Other undisclosed current assets 826321853762549515
Total current assets: 107,393106,470149,897108,752101,725110,350
Noncurrent Assets
Operating lease, right-of-use asset 788318589
Property, plant and equipment 14152113168154400
Other noncurrent assets 1,045647729549319223
Total noncurrent assets: 1,9741,0171,431717473623
TOTAL ASSETS: 109,367107,487151,328109,469102,198110,973
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 9,7897,4315,33410,0997,4727,725
Employee-related liabilities 6,7254,3593,420   
Accounts payable 2,1582,2051,0191,2871,3392,604
Accrued liabilities 9068678958,8126,1335,121
Debt   187   
Derivative instruments and hedges, liabilities   45,935   
Other undisclosed current liabilities 3,0951,92213,153   
Total current liabilities: 12,8849,35364,60910,0997,4727,725
Noncurrent Liabilities
Long-term debt and lease obligation 4851753744,891  
Long-term debt, excluding current maturities    4,891  
Operating lease, liability 485175374
Other undisclosed noncurrent liabilities (485)(175)    
Total noncurrent liabilities: 4851753744,891  
Total liabilities: 13,3699,52864,98314,9907,4727,725
Equity
Equity, attributable to parent 95,99897,95986,34594,47994,726103,248
Preferred stock   1   
Common stock 161174745230
Additional paid in capital 1,037,230944,537851,957771,817718,751685,272
Accumulated deficit (941,248)(846,589)(765,687)(677,412)(624,077)(582,054)
Total equity: 95,99897,95986,34594,47994,726103,248
TOTAL LIABILITIES AND EQUITY: 109,367107,487151,328109,469102,198110,973

Income Statement (P&L) ($ in thousands)

3/31/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues  300    
Gross profit:  300    
Operating expenses (94,585)(65,241)(66,992)(55,417)(42,619)(48,075)
Operating loss: (94,585)(64,941)(66,992)(55,417)(42,619)(48,075)
Nonoperating income (expense) (77)(15,819)(21,443)1,780760351
Other nonoperating income (expense) (77)421(517)1,780760351
Loss from continuing operations before income taxes: (94,662)(80,760)(88,435)(53,637)(41,859)(47,724)
Income tax expense (benefit) 3(142)160302(156)(143)
Loss from continuing operations: (94,659)(80,902)(88,275)(53,335)(42,015)(47,867)
Loss before gain (loss) on sale of properties:(94,659)(80,902)(88,275)(53,335)(42,015)(47,867)
Net loss available to common stockholders, diluted: (94,659)(80,902)(88,275)(53,335)(42,015)(47,867)

Comprehensive Income ($ in thousands)

3/31/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (94,659)(80,902)(88,275)(53,335)(42,015)(47,867)
Comprehensive loss, net of tax, attributable to parent: (94,659)(80,902)(88,275)(53,335)(42,015)(47,867)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: